drugset / Trial / NCT03581630

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

NCT03581630

Completed 72 enrolled Gangnam Severance Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

Obesity among breast cancer survivors is known to be associated with recurrence and other co-morbidities. However, there have been no studies on weight reduction program combining diet and anti-obesity drug for obese breast cancer survivors. The purpose of this randomized clinical trial is to examine the effects of Mediterranean Diet and naltrexone/bupropion treatment on inflammation and metabolic risk factors in overweight or obese breast cancer patients after breast cancer treatment.

Timeline

Start
2017-07-29
Primary completion
2018-07-22
Completion
2018-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 90 mg Oral
Subject Naltrexone Small molecule 8 mg Oral